RightFit
RecruitingPhase not listed

Understanding New Cachexia Subtypes Through Observational Epidemiological Research

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

The UNCOVER study follows adults with advanced lung, pancreatic, or colorectal cancer to learn about different types of cancer cachexia. Cachexia is a loss of weight, muscle, and body fat that can make daily tasks harder. This study collects health information over time rather than testing a treatment.

The UNCOVER study is a longitudinal observational cohort focused on patients at high risk for cancer cachexia. At Kaiser Permanente Northern California, up to 800 individuals with advanced or unresectable non-small cell lung cancer, pancreatic adenocarcinoma, or colorectal cancer will be enrolled, as these malignancies carry a substantial risk of cancer cachexia, which is characterized by progressive loss of weight, muscle, and adipose tissue, accompanied by functional decline and reduced quality of life. Data collected includes demographic, physiologic, and clinical data, including tumor characteristics and biomarkers of inflammation, hormonal and metabolic status, body composition, physical function, and patient reported outcomes. Investigators will identify patient phenotypes (i.e., subgroups) that may reflect distinct biological or clinical pathways underlying cancer cachexia. By characterizing heterogeneity in cancer cachexia, this study aims to inform the development of improved diagnostic criteria and more targeted therapeutic strategies, ultimately enhancing clinical trial design and supportive care for patients with advanced colorectal, lung, or pancreatic cancer.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Have non-small cell lung cancer, pancreatic adenocarcinoma, or colorectal cancer that cannot be removed by surgery or is stage IV (has spread to distant body parts).
  • You do not need to have cachexia to join.
  • Plan to start your first course of cancer drug treatment within the next 6 weeks, or have started it within the past 6 weeks.
  • Past cancer drug treatment given before or after surgery is allowed if the cancer returned and that treatment was more than 6 months before joining.
  • Have an ECOG activity score of 0, 1, or 2: you can care for yourself and are up and about for more than half of your waking hours.
  • Be able to understand, speak, and read English.
  • Be age 18 or older.

Who can't join

  • Your care team says it is unsafe for you to do the study's arm curl, standing, or walking tests.
  • Have major surgery planned within 3 months after joining.
  • Have had chemotherapy or surgery for a separate cancer within the past 3 years, except for non-melanoma skin cancer.
  • Are pregnant or gave birth within the past 6 months.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Have a primary diagnosis of unresectable or Stage IV 1) non-small cell lung cancer (NSCLC), 2) pancreatic adenocarcinoma, or 3) colorectal cancer (CRC). Note: Patients do not need to have cachexia to be eligible * Plan to start first line systemic anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy) in the next 6 weeks or has started first-line systemic therapy in the previous 6 weeks. Note: Patients who received systemic anti-cancer therapy previously as part of adjuvant or neoadjuvant therapy and have since recurred are still eligible if such treatment was longer than 6 months prior to enrollment. * Have an an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. * Be able to understand, speak and read English. * Be 18 years or older Exclusion Criteria: * Have contraindications to physical function assessments (30-second bicep curl, Timed-Up-And-Go test, or 30-Second Sit to Stand test) per the treating provider or their designee. * Have any planned major surgeries within the next 3 months after enrollment to the best knowledge of the investigator/treating provider or their designee. * Have received chemotherapy or surgery for separate primary cancer within the past 3 years other than non-melanoma skin cancer. * Be pregnant or within 6 months postpartum.

Study sites (1)

CA